Last reviewed · How we verify
LTRA
LTRA, marketed by Hoffmann-La Roche, is a drug that interacts with a specific biological target to address its primary indication, currently holding a established position in the market. A key strength of LTRA is its key composition patent, which is set to expire in 2028, providing a period of exclusivity and protection against generic competition. The primary risk facing LTRA is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | LTRA |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) (PHASE2)
- A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (PHASE3)
- Characteristics of Pts Initiating Spiriva Respimat in Asthma
- To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis (PHASE1)
- Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations (PHASE2)
- Pediatric Arm of DZL All Age Asthma Cohort
- 3TR Asthma Biologics Cohort (ABC) Study
- Evaluation of Dupilumab in Children With Uncontrolled Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |